Cybin Inc (CYBN) - Total Liabilities
Based on the latest financial reports, Cybin Inc (CYBN) has total liabilities worth CA$16.18 Million CAD (≈ $11.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cybin Inc - Total Liabilities Trend (2020–2025)
This chart illustrates how Cybin Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Cybin Inc to evaluate short-term liquidity relative to the company's equity base.
Cybin Inc Competitors by Total Liabilities
The table below lists competitors of Cybin Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangxi Hechi Chemical Co Ltd
SHE:000953
|
China | CN¥100.06 Million |
|
Korea Environment Technology Co. LTD
KQ:029960
|
Korea | ₩53.13 Billion |
|
Hubtown Limited
NSE:HUBTOWN
|
India | Rs31.54 Billion |
|
Pekat Group Bhd
KLSE:0233
|
Malaysia | RM270.27 Million |
|
Materialise NV
F:06MA
|
Germany | €164.14 Million |
|
Promotora Ambiental S.A.B. de C.V
MX:PASAB
|
Mexico | MX$5.01 Billion |
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
USA | $12.39 Million |
|
Brompton Split Banc Corp
TO:SBC
|
Canada | CA$237.75 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Cybin Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cybin Inc (CYBN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cybin Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cybin Inc (2020–2025)
The table below shows the annual total liabilities of Cybin Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | CA$21.42 Million ≈ $15.49 Million |
+112.14% |
| 2024-03-31 | CA$10.10 Million ≈ $7.30 Million |
+78.28% |
| 2023-03-31 | CA$5.66 Million ≈ $4.10 Million |
-28.39% |
| 2022-03-31 | CA$7.91 Million ≈ $5.72 Million |
+31.93% |
| 2021-03-31 | CA$5.99 Million ≈ $4.34 Million |
+2179.09% |
| 2020-03-31 | CA$263.00K ≈ $190.25K |
-- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more